HeartBeam, a medical technology company focused on transforming cardiac care, announced that its management team will participate in several investor and industry conferences throughout March 2026. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors.
The executives will also participate in the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion on technologies advancing healthy aging. Additionally, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30.
At the cardiology conference, the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. This technology represents a significant advancement in cardiac monitoring, as HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG.
The company's platform technology is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence to physicians. This capability allows healthcare providers to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of traditional medical facilities. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025.
HeartBeam holds over 20 issued patents related to technology enablement, positioning the company at the forefront of innovation in cardiac monitoring. The company's participation in these conferences comes at a critical time as healthcare systems worldwide seek more efficient and accessible cardiac monitoring solutions. The ability to monitor patients remotely with hospital-grade accuracy could significantly reduce healthcare costs while improving patient outcomes, particularly for those with chronic cardiac conditions or those at risk of cardiac events.
For more information about the company, visit https://ibn.fm/BEAT. The full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer.
